Electronic certificates of origin enable preferential tariffs under the India-New Zealand FTA when format, verification, and filing requirements are m...
Customs approval for liquid cargo exports extends designated jetty operations while existing boarding station and customs area limits remain unchanged...
Mandatory compliance document verification now conditions out-of-charge clearance for imported cosmetics, drugs, and medical devices through PGA-facil...
Double taxation of turnover requires holistic verification across separately registered units and permits limited rectification of overlapping assessm...
DGFT amended SION A-222 under FTP-2023 regarding export norms for Erythromycin Stearate tablets. The revised norm establishes that for manufacturing one tablet of Erythromycin Stearate (250 mg), the permitted import quantity of Erythromycin Stearate is 334 mg. The amendment, effective immediately, allows pro-rata calculations for other product variants. This modification, executed under paragraphs 1.03 and 2.04 of FTP-2023, standardizes the input-output ratio for pharmaceutical manufacturers engaged in export of Erythromycin formulations, ensuring regulatory compliance and manufacturing consistency.
DGFT amended SION A-222 under FTP-2023 regarding export norms for Erythromycin Stearate tablets. The revised norm establishes that for manufacturing one tablet of Erythromycin Stearate (250 mg), the permitted import quantity of Erythromycin Stearate is 334 mg. The amendment, effective immediately, allows pro-rata calculations for other product variants. This modification, executed under paragraphs 1.03 and 2.04 of FTP-2023, standardizes the input-output ratio for pharmaceutical manufacturers engaged in export of Erythromycin formulations, ensuring regulatory compliance and manufacturing consistency.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
